Strategic growth Fortrea is a spun-off, growing global CRO with recent acquisitions and expansion activity, signaling a potential need for integrated trial management, pharmacovigilance, and post-approval services across larger pipelines.

Technology enablement Fortrea launched Fortrea Intelligent Technology (FIT) and employs a modern tech stack (Ansible, Snowflake, Workday, VMWare, etc.), presenting opportunities to cross-sell technology-enabled trial solutions and data capabilities to improve trial efficiency and data integration.

Financial momentum Recent revenue milestones and earnings beats, alongside a strategic CFO appointment, indicate a focus on returning to growth and scale, suggesting readiness for larger multi-year outsourcing deals and expanded service scopes.

Global footprint With presence in over 90 countries and a large investigator site network, there are opportunities to expand in regional markets, enroll diverse patient populations, and strengthen site management and pharmacovigilance offerings.

Pipeline readiness Fortrea’s end-to-end clinical development capabilities from Phase I to post-approval, plus upgrades in pharmacovigilance and safety monitoring, point to cross-sell opportunities across therapeutic areas and lifecycle services for biopharma and medical device clients.